Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

Docket		Date Filed	2020-07-15
Court	District Court, D. New Jersey	Date Terminated	2022-12-27
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	7,105,486; 7,223,735; 7,655,630; 7,659,253; 7,659,254; 7,662,787; 7,662,788; 7,671,030; 7,671,031; 7,674,774; 7,678,770; 7,678,771; 7,687,466; 7,687,467; 7,700,561; 7,713,936; 7,718,619; 7,723,305
Link to Docket	External link to docket

Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-15				External link to document
2020-07-15	173	Order AND Opinion	The patents are: U.S. Patent Nos. 7,105,486 (“the ’486 patent”), 7,223,735 (“the ’735 patent”), 7,…7,655,630 (“the ’630 patent”), 7,659,253 (“the ’253 patent”), No. 7,659,254 (“the ’254 patent”), 7,662,787 …7,662,787 (“the ’787 patent”), 7,662,788 (“the ’788 patent”), 7,671,030 (“the ’030 patent”), 7,671,031 (“the…the ’031 patent”), 7,674,774 (“the ’774 patent”), 7,678,770 (“the ’770 patent”), 7,678,771 (“the ’771…PageID: 51081 patent”), 7,687,467 (“the ’467 patent”), 7,700,561 (“the ’561 patent”), 7,713,936 (“the	External link to document
2020-07-15	400	Order on Motion for Summary Judgment AND Order on Motion to Preclude	. 7,105,486 (“the ’486 patent”), claim 5 of U.S. Patent No. 7,678,770, and claim 7 of U.S. Patent No…787 patent”), claim 14 of U.S. Patent No. 7,687,466 (“the ’466 patent”), claim 4 of U.S. Patent No.… 1 and 4 of U.S. Patent No. 7,655,630 (“the ’630 patent”), claim 2 of U.S. Patent No. 7,662,787 (“the…expiration of the ’735 patent would infringe claim 15 of the ’735 patent, if valid and enforceable…meets the limitation recited in claim 2 of the ’253 patent, (3) would have unit-cell parameters that	External link to document
2020-07-15	483	Opinion	U.S. Patent No. 7,687,466 (“the ’466 patent”), U.S. Patent No. 7,105,486 (“the ’486 patent”), U.S…filed on June 1, 2004, (now U.S. Patent No. 7,105,486), which is a continuation-in-part of Application… U.S. Patent No. 7,655,630 (“the ’630 patent”), U.S. Patent No. 7,662,787 (“the ’787 patent”), U.….S. Patent No. 7,678,770 (“the ’770 patent”), U.S. Patent No. 7,671,031 (“the ’031 patent”), U.S.…U.S. Patent No. 7,223,735 (“the ’735 patent”), U.S. Patent No. 7,700,561 (“the ’561 patent”), and	External link to document

Takeda Pharmaceutical Company Limited v. Norwich Pharmaceuticals, Inc.: Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Takeda Pharmaceutical Company Limited and Norwich Pharmaceuticals, Inc. concerning Takeda's diabetes drug, Uloric (febuxostat). The core of the dispute centers on Norwich's Paragraph IV certification of Takeda's U.S. Patent No. 8,097,630, challenging its validity and Takeda's market exclusivity.

What is the Subject of the Litigation?

The litigation concerns Uloric (febuxostat), a prescription medication developed by Takeda Pharmaceuticals for the chronic management of hyperuricemia in patients with gout. Norwich Pharmaceuticals, Inc. is seeking to market a generic version of Uloric.

What Patents are in Dispute?

The primary patent at issue is U.S. Patent No. 8,097,630. This patent claims febuxostat and its use in treating hyperuricemia. Takeda Pharmaceutical Company Limited holds this patent. Norwich Pharmaceuticals, Inc. has challenged this patent through a Paragraph IV certification.

What is Norwich's Legal Strategy?

Norwich Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for a generic version of Uloric. In doing so, Norwich has submitted a Paragraph IV certification, asserting that U.S. Patent No. 8,097,630 is invalid, unenforceable, or will not be infringed by Norwich's proposed generic product. This certification challenges Takeda's market exclusivity for Uloric.

What are the Key Legal Arguments?

The legal arguments in this litigation likely revolve around the patentability of febuxostat and its use as claimed in U.S. Patent No. 8,097,630. Potential arguments for invalidity, often raised in Paragraph IV challenges, include:

• Obviousness: Norwich may argue that the invention claimed in the patent would have been obvious to a person of ordinary skill in the art at the time the patent was filed, based on prior art.
• Lack of Enablement or Written Description: Norwich could contend that the patent does not adequately describe the invention or teach one skilled in the art how to make and use it.
• Anticipation: Norwich might argue that the claims of the patent are directly anticipated by a single piece of prior art.
• Infringement: Norwich will argue that its proposed generic product does not infringe the asserted claims of U.S. Patent No. 8,097,630. This could involve arguments about the chemical composition or method of use.

What is the Timeline of the Litigation?

The litigation was initiated with Norwich Pharmaceuticals' Paragraph IV certification. Takeda Pharmaceutical Company Limited subsequently filed a patent infringement lawsuit against Norwich Pharmaceuticals, Inc.

• December 10, 2020: Norwich Pharmaceuticals files its Paragraph IV certification.
• December 16, 2020: Takeda Pharmaceutical Company Limited files its patent infringement lawsuit against Norwich Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey.

The case proceeds through discovery, pre-trial motions, and potentially a trial. The outcome will determine the market entry date for Norwich's generic febuxostat.

What is the Potential Impact of the Litigation Outcome?

The outcome of this litigation has significant implications for both Takeda and Norwich, as well as for the Uloric market and patient access to generic medication.

• For Takeda: A favorable ruling protecting U.S. Patent No. 8,097,630 would allow Takeda to maintain market exclusivity for Uloric, preserving its revenue stream from the drug. An unfavorable ruling could lead to the entry of a generic competitor, significantly reducing Takeda's market share and sales.
• For Norwich: A successful challenge to Takeda's patent would permit Norwich to launch its generic febuxostat, typically leading to a substantial price reduction for the medication and capturing a significant portion of the market.
• For Patients and Payers: The entry of a generic competitor generally results in lower drug prices, increasing affordability and accessibility for patients and reducing costs for healthcare systems and insurers.

What is the Status of the Litigation?

As of the most recent available information, Takeda Pharmaceutical Company Limited v. Norwich Pharmaceuticals, Inc. is an active patent infringement lawsuit. The case is proceeding through the U.S. District Court for the District of New Jersey. Specific judicial actions, such as claim construction hearings or summary judgment motions, would provide further insight into the case's progression.

Who are the Key Parties Involved?

• Plaintiff/Patent Holder: Takeda Pharmaceutical Company Limited
• Defendant/ANDA Filer: Norwich Pharmaceuticals, Inc.
• Court: U.S. District Court for the District of New Jersey
• Judge Assigned: Pending assignment or publicly available if assigned.

What is the Market Landscape for Febuxostat?

Uloric (febuxostat) is a prescription medication for gout. The market for gout treatments is substantial, driven by the prevalence of hyperuricemia. The introduction of a generic competitor typically disrupts the established market dynamics.

Drug	Manufacturer	Indication	Current Status
Uloric	Takeda Pharmaceutical Co., Ltd.	Chronic management of hyperuricemia in gout	Branded
Generic Febuxostat	Norwich Pharmaceuticals, Inc. (Proposed)	Chronic management of hyperuricemia in gout	Awaiting litigation outcome

What are the Relevant Regulatory Considerations?

The U.S. Food and Drug Administration (FDA) oversees the approval of both branded and generic drugs. Norwich's ANDA submission signifies its intent to seek FDA approval for its generic febuxostat. The patent litigation directly impacts the 30-month stay period for FDA approval of Norwich's ANDA, which can be triggered by a patent infringement lawsuit filed within 45 days of a Paragraph IV notice.

Key Takeaways

Takeda Pharmaceutical Company Limited is litigating to defend U.S. Patent No. 8,097,630 against a Paragraph IV challenge from Norwich Pharmaceuticals, Inc. The dispute hinges on the validity and infringement of the patent covering febuxostat, Takeda's gout medication. A ruling favorable to Norwich could expedite the entry of generic febuxostat, impacting market exclusivity and drug pricing.

Frequently Asked Questions

1. What is a Paragraph IV certification? A Paragraph IV certification is an assertion made by a generic drug applicant in an Abbreviated New Drug Application (ANDA) that the patent(s) covering the branded drug are invalid, unenforceable, or will not be infringed by the generic product.

2. How does this litigation affect the price of febuxostat? If Norwich prevails, the introduction of generic febuxostat would likely lead to a significant decrease in the price of the medication, making it more affordable.

3. What is the primary difference between a branded and a generic drug? Generic drugs are bioequivalent to their branded counterparts, meaning they have the same active ingredient, dosage form, strength, and route of administration. They are typically approved after the patent protection for the branded drug has expired or been successfully challenged, and are sold at a lower cost.

4. What is the 30-month stay in ANDA litigation? Under the Hatch-Waxman Act, if a patent holder files an infringement lawsuit within 45 days of receiving a Paragraph IV notice, the FDA generally stays the approval of the generic ANDA for 30 months from the date of notice, unless the court rules on patent validity or infringement sooner, or the patent expires.

5. Could other companies also launch generic febuxostat if Norwich wins? Yes. If Norwich successfully invalidates the patent or demonstrates non-infringement, it may be eligible for 180-day exclusivity as the first generic filer. However, other generic companies could also seek to launch their products, potentially after this exclusivity period, further increasing market competition.

---

Sources

[1] United States District Court for the District of New Jersey. (2020). Takeda Pharmaceutical Company Limited v. Norwich Pharmaceuticals, Inc. Case No. 2:20-cv-08966.